BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

About Apidra (R) Apidra (R) is a rapid-acting insulin that can be administered using an insulin infusion pump, vial and syringe, the OptiClik (R) reusable insulin pen, or intravenously under proper ...

Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra, is now available. Apidra SoloSTAR makes administration of insulin more ...

The FDA has approved Apidra (insulin glulisine [rDNA origin] injection, from sanofi-aventis) for the treatment of type 1 diabetes in children ≥4 years old. This approval was based on a 26-week, ...

Oct. 5, 2004 — The European Commission has approved for use in the European Union an expanded dosing indication for darbepoetin alfa, etanercept for moderate to severe plaque psoriasis, insulin ...

European Commission approves Apidra for diabetes Apidra has a rapid onset and short duration of action which allows covering the postprandial hyperglycaemic peaks. It should normally be used in ...

To earn CME related to this news article, click here. January 6, 2009 — The US Food and Drug Administration (FDA) has approved revisions to the safety labeling, adding adverse event information for ...

PARIS, Feb 26 (Reuters) - Sanofi-Aventis has won U.S. approval to market its Apidra Solostar injection pen which contains insulin to treat diabetes, the world's third-biggest drugmaker said on ...

BRIDGEWATER, N.J. The Food and Drug Administration has approved Apidra, a drug for improving glycemic control in diabetic children aged 4 and older, manufacturer Sanofi-Aventis said Wednesday. The FDA ...

- First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin "Comparison of 3 intensified ...

Sanofi-aventis announces results from a new study show that adding Apidra to a Basal insulin and Oral antidiabetic drug Therapy (BOT+ or Basal plus) may provide an effective treatment option for ...